Furthermore, the heterogeneity was considerable and follow-up lengths varied from three years to 12
Far more energy and much less brain fog
Societa Italiana di Diabetologia) Italian Guidelines stated that GLP1-RA can be prescribed as a first line therapy in T2DM with a previous cardiovascular event
Key Results Semaglutide vs Sitagliptin HR 0.58 (95% CI, 0.510.65) 42% lower risk 1-yr absolute risk: 5.5% vs 8.6% NNT 31 Tirzepatide vs Sitagliptin HR 0.42 (95% CI, 0.310.57) 58% lower risk 1-yr absolute risk: 3.6% vs 7.5% NNT 26 Tirzepatide vs Semaglutide HR 0.86 (95% CI, 0.701.06) no statistically significant difference Safety: No excess signal for GI, infections, or serious AEs across GLP-1/dual arms
Sign up to the WOMEN'S HEALTH NEWSLETTER Sydney Wingfield is a freelance writer specializing in the beauty and lifestyle spaces
Exenatide, has emerged as a potential solution, however, its impact on cognitive function in individuals with raised ICP remains unexplored
